

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

December 22, 2017

Jed A. Latkin Chief Financial Officer and Chief Operating Officer Navidea Biopharmaceuticals, Inc. 4995 Bradenton Avenue, Suite 240 Dublin, Ohio 43017-3552

> Re: Navidea Biopharmaceuticals, Inc. Registration Statement on Form S-3 Filed December 15, 2017 File No. 333-222092

Dear Mr. Latkin:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Chris Edwards at (202) 551-6761 with any questions.

Division of Corporation Finance Office of Healthcare & Insurance

cc: Faith L. Charles, Esq.